- Home
- BRY vs ACIU Comparison
BRY vs ACIU Comparison
Compare BRY & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- ACIU
- Stock Information
- Founded
- BRY 1909
- ACIU 2003
- Country
- BRY United States
- ACIU Switzerland
- Employees
- BRY N/A
- ACIU N/A
- Industry
- BRY Oil & Gas Production
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- BRY Energy
- ACIU Health Care
- Exchange
- BRY Nasdaq
- ACIU Nasdaq
- Market Cap
- BRY 367.0M
- ACIU 294.9M
- IPO Year
- BRY N/A
- ACIU 2016
- Fundamental
- Price
- BRY $5.00
- ACIU $2.68
- Analyst Decision
- BRY Hold
- ACIU Strong Buy
- Analyst Count
- BRY 1
- ACIU 2
- Target Price
- BRY $5.00
- ACIU $12.00
- AVG Volume (30 Days)
- BRY 1.2M
- ACIU 150.6K
- Earning Date
- BRY 03-05-2025
- ACIU 03-13-2025
- Dividend Yield
- BRY 15.00%
- ACIU N/A
- EPS Growth
- BRY 73.42
- ACIU N/A
- EPS
- BRY 1.06
- ACIU N/A
- Revenue
- BRY $806,733,000.00
- ACIU $48,505,404.00
- Revenue This Year
- BRY N/A
- ACIU $85.33
- Revenue Next Year
- BRY N/A
- ACIU $80.69
- P/E Ratio
- BRY $4.70
- ACIU N/A
- Revenue Growth
- BRY N/A
- ACIU 4097200.00
- 52 Week Low
- BRY $3.72
- ACIU $2.25
- 52 Week High
- BRY $8.88
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- BRY 73.47
- ACIU 40.60
- Support Level
- BRY $4.68
- ACIU $2.56
- Resistance Level
- BRY $5.09
- ACIU $2.83
- Average True Range (ATR)
- BRY 0.20
- ACIU 0.17
- MACD
- BRY 0.11
- ACIU -0.00
- Stochastic Oscillator
- BRY 92.86
- ACIU 22.47
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.